1. Home
  2. COCP vs OXBR Comparison

COCP vs OXBR Comparison

Compare COCP & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCP
  • OXBR
  • Stock Information
  • Founded
  • COCP 2006
  • OXBR 2013
  • Country
  • COCP United States
  • OXBR Cayman Islands
  • Employees
  • COCP N/A
  • OXBR N/A
  • Industry
  • COCP Biotechnology: Pharmaceutical Preparations
  • OXBR Property-Casualty Insurers
  • Sector
  • COCP Health Care
  • OXBR Finance
  • Exchange
  • COCP Nasdaq
  • OXBR Nasdaq
  • Market Cap
  • COCP 15.7M
  • OXBR 16.9M
  • IPO Year
  • COCP N/A
  • OXBR 2014
  • Fundamental
  • Price
  • COCP $1.80
  • OXBR $2.21
  • Analyst Decision
  • COCP Strong Buy
  • OXBR Strong Buy
  • Analyst Count
  • COCP 1
  • OXBR 1
  • Target Price
  • COCP $6.00
  • OXBR $5.00
  • AVG Volume (30 Days)
  • COCP 21.6K
  • OXBR 191.0K
  • Earning Date
  • COCP 08-13-2025
  • OXBR 08-07-2025
  • Dividend Yield
  • COCP N/A
  • OXBR N/A
  • EPS Growth
  • COCP N/A
  • OXBR N/A
  • EPS
  • COCP N/A
  • OXBR N/A
  • Revenue
  • COCP N/A
  • OXBR $1,363,000.00
  • Revenue This Year
  • COCP N/A
  • OXBR $497.99
  • Revenue Next Year
  • COCP N/A
  • OXBR $42.14
  • P/E Ratio
  • COCP N/A
  • OXBR N/A
  • Revenue Growth
  • COCP N/A
  • OXBR N/A
  • 52 Week Low
  • COCP $1.12
  • OXBR $1.27
  • 52 Week High
  • COCP $3.26
  • OXBR $5.81
  • Technical
  • Relative Strength Index (RSI)
  • COCP 69.71
  • OXBR 61.45
  • Support Level
  • COCP $1.46
  • OXBR $1.85
  • Resistance Level
  • COCP $1.60
  • OXBR $2.26
  • Average True Range (ATR)
  • COCP 0.08
  • OXBR 0.26
  • MACD
  • COCP 0.02
  • OXBR 0.05
  • Stochastic Oscillator
  • COCP 92.31
  • OXBR 83.33

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

Share on Social Networks: